A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Mirikizumab (Primary) ; Secukinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms OASIS-2
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 02 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Apr 2019 Planned primary completion date changed from 18 Mar 2020 to 3 Mar 2020.
- 25 Mar 2019 Planned End Date changed from 10 Jun 2020 to 11 Dec 2020.